More than 80% of pediatric solid organ transplant (SOT) recipients now survive into young adulthood and many encounter transplant-related complications. Post-transplantation diabetes mellitus (PTDM), sometimes also referred to as post-transplant diabetes or new onset diabetes after transplant, occurs in 3–20% of pediatric SOT recipients depending upon the organ transplanted, age at transplantation, immunosuppressive regimen, family history, and time elapsed since transplant. To diagnose PTDM, hyperglycemia must persist beyond the initial hospitalization for transplantation when a patient is on stable doses of immunosuppressive medications. Though standard diagnostic criteria used by the American Diabetes Association (ADA) to diagnose diabetes are employed, clinicians need to be aware of the limitations of using these criteria in this unique patient population. Management of PTDM parallels strategies used for type 2 diabetes (T2D), while also carefully considering comorbidities and potential interactions with immunosuppressive medications in these patients. In caring for patients with PTDM, it is important to be familiar with these interactions and comorbidities in order to coordinate care with the transplant team and optimize outcomes for these patients.
Horm Res Paediatr

中文翻译：

---

儿科患者的移植后糖尿病

超过 80% 的儿科实体器官移植 (SOT) 接受者现在可以活到成年，并且许多人会遇到与移植相关的并发症。移植后糖尿病 (PTDM)，有时也称为移植后糖尿病或移植后新发糖尿病，发生在 3-20% 的儿科 SOT 受者中，具体取决于移植器官、移植年龄、免疫抑制方案、家族史，以及移植后经过的时间。为了诊断 PTDM，当患者服用稳定剂量的免疫抑制药物时，高血糖症必须持续超过最初的移植住院治疗。尽管采用了美国糖尿病协会 (ADA) 用于诊断糖尿病的标准诊断标准，临床医生需要意识到在这个独特的患者群体中使用这些标准的局限性。PTDM 的管理与用于 2 型糖尿病 (T2D) 的策略相似，同时还要仔细考虑这些患者的合并症和与免疫抑制药物的潜在相互作用。在护理 PTDM 患者时，重要的是要熟悉这些相互作用和合并症，以便与移植团队协调护理并优化这些患者的结果。
儿科荷尔蒙